Comparative Pharmacology
Head-to-head clinical analysis: KANTREX versus NEOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KANTREX versus NEOMYCIN SULFATE.
KANTREX vs NEOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis and causing mRNA misreading.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death by disrupting the cytoplasmic membrane.
15 mg/kg/day IM or IV divided every 8-12 hours (not to exceed 1.5 g/day)
1-2 g orally 4 times daily (8-16 g/day) for hepatic encephalopathy or intraluminal infection; 0.5-1 g orally 4 times daily for preoperative bowel preparation.
None Documented
None Documented
2-3 hours (normal renal function); prolonged to 30-50 hours in anuria; clinically significant accumulation in renal impairment requires monitoring
2-3 hours (normal renal function); prolonged to 20-60 hours in anuria
Renal: 80-100% as unchanged drug via glomerular filtration; fecal: <1%
Renal (glomerular filtration) >90% unchanged; small amount biliary/fecal (<3%)
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic